Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Multiple Myeloma 337Neoplasms, Plasma Cell 56Precursor Cell Lymphoblastic Leukemia-Lymphoma 54Recurrence 50Lymphoma 48Leukemia 39Neoplasms 27Lymphoma, Mantle-Cell 27Burkitt Lymphoma 26Lymphoma, Large B-Cell, Diffuse 23Immunoglobulin Light-chain Amyloidosis 23Lymphoma, Non-Hodgkin 22Waldenstrom Macroglobulinemia 21Lymphoma, Follicular 17Leukemia, Lymphocytic, Chronic, B-Cell 16Hodgkin Disease 14Nausea 12Lymphoma, Extranodal NK-T-Cell 12Lymphoma, B-Cell, Marginal Zone 12Vomiting 11Smoldering Multiple Myeloma 11Prostatic Neoplasms 11Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Breast Neoplasms 11Renal Insufficiency 10Neoplasm Metastasis 9Lymphoma, Large-Cell, Immunoblastic 9Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 8Leukemia, Biphenotypic, Acute 7

Interventions

Paclitaxel 2Injections 2toripalimab 1tislelizumab 1surufatinib 1sotorasib 1osimertinib 1netrin-1 inhibitor NP137 1lazertinib 1fluzoparib 1camrelizumab 1Panitumumab 1PM 01183 1Nivolumab 1Ipilimumab 1HMPL-013 1Erlotinib Hydrochloride 1Dexamethasone 1Calcium Dobesilate 1Bortezomib 1Bevacizumab 13-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Solid Tumors × Dexamethasone × Clear all
NCT02057380 2024-11-20

A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

Astellas Pharma Inc

Phase 2 Completed
13 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡